The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.
Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...
Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results